New Key Statistics Module, Z-Score and F-Score
OTCPK:ENZN Key Ratios
| Market Cap $ M | 7.79 |
| Enterprise Value $ M | -38.14 |
| P/E(ttm) | 52.50 |
| PE Ratio without NRI | 52.50 |
| Forward PE Ratio | -- |
| Price/Book | 2.63 |
| Price/Sales | -- |
| Price/Free Cash Flow | 5.82 |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | 0.002 |
| Beneish M-Score | -2.11 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 34.93 |
| EV-to-EBITDA | 34.93 |
| PEG | -- |
| Shares Outstanding M | 74.21 |
| Net Margin (%) | 6,111.54 |
| Operating Margin % | -4,200.00 |
| Pre-tax Margin (%) | 5,465.39 |
| Quick Ratio | 113.75 |
| Current Ratio | 113.75 |
| ROA % (ttm) | 3.38 |
| ROE % (ttm) | 52.69 |
| ROIC % (ttm) | -433.32 |
| Dividend Yield % | -- |
| Altman Z-Score | -0.68 |
ENZN Number of Guru Trades
ENZN Volume of Guru Trades
Gurus Latest Trades with OTCPK:ENZN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
OTCPK:ENZN is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Enzon Pharmaceuticals Inc Insider Transactions
No Available Data
News about OTCPK:ENZN
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers